Nachrichten zur PTC Therapeutics Inc. Aktie

PTC Therapeutics: Durchbruch bei seltenen Krankheiten sichert Rekordumsatz

PTC Therapeutics ist ein führendes Biopharma-Unternehmen, das sich auf die Entwicklung und Vermarktung von Therapien für seltene genetische Erkrankungen…

Compared to Estimates, PTC Therapeutics (PTCT) Q3 Earnings: A Look at Key Metrics

The headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended September 2025,…

PTC Therapeutics (PTCT) Reports Q2 Earnings: What Key Metrics Have to Say

The headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended June 2025,…

PTC Therapeutics (PTCT) Reports Q2 Loss, Beats Revenue Estimates

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of +22.43% and +4.82%, respectively, for the quarter ended June 2025. Do…

PTC Therapeutics (PTCT) Surges 11.2%: Is This an Indication of Further Gains?

PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings…

PTC Therapeutics stock soars after FDA approval of PKU treatment By Investing.com

PTC Therapeutics stock soars after FDA approval of PKU treatment…

US FDA approves PTC Therapeutics’ metabolic disorder drug By Reuters

US FDA approves PTC Therapeutics’ metabolic disorder drug…

THC Therapeutics, Inc. Announces Acquisition of SugarTop Buddery

THC Therapeutics, Inc. Announces Acquisition of SugarTop Buddery…

THC Therapeutics, Inc. Announces Acquisition of Oregon and California Consortium of Cannabis Companies

THC Therapeutics, Inc. Announces Acquisition of Oregon and California Consortium of Cannabis Companies…

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

NEW YORK, May 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

PTC Therapeutics, Inc. (PTCT) Q1 2025 Earnings Call Transcript

…

PTC Therapeutics (PTCT) Q1 2025 Earnings Call

Image source: The Motley Fool. DATETuesday, May 6, 2025 at 4:30 p.m. ETCALL PARTICIPANTSChief Executive Officer — Matthew KleinChief Operating Officer…

PTC Therapeutics stock drops after Huntington’s study update By Investing.com

PTC Therapeutics stock drops after Huntington’s study update…

PTC Therapeutics (PTCT) Earnings Expected to Grow: Should You Buy?

PTC Therapeutics (PTCT) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its…

PTC Therapeutics: Upside In Rare Disease Innovation

…

PTC Therapeutics (PTCT) Reports Q4 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for PTC Therapeutics (PTCT) give a sense of how its business performed in the quarter…

PTC Therapeutics (PTCT) Reports Q4 Loss, Lags Revenue Estimates

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of 75% and 3.96%, respectively, for the quarter ended December 2024. Do…

PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming…

PTC Therapeutics receives priority review for its nervous system disorder treatment

…

PTC Therapeutics (PTCT) Moves 9.0% Higher: Will This Strength Last?

PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest…

PTC Therapeutics rises 9% after Cantor raises price target to Street high

…

Novartis Hold

ANA FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Novartis mit einem Kursziel von 100 Franken auf "Hold" belassen. Die…

Deutsche Bank Research belässt Novartis auf Hold

ANA FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Novartis mit einem Kursziel von 100 Franken auf "Hold" belassen. Die…

PTC Therapeutics: ALS Drug Fail Kicks Off Critical Year Of Catalysts

…

PTC Therapeutics, Inc. (PTCT) Q3 2024 Earnings Call Transcript

…

PTCT Stock Rises on Positive Updates on Friedreich Ataxia Program

PTC Therapeutics announces positive results from long-term treatment studies on vatiquinone for the treatment of Friedreich ataxia.…

PTC Therapeutics (PTCT) Surges 16.5%: Is This an Indication of Further Gains?

PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings…

PTC Therapeutics: Positive HD Data Along With NDA Submission Brings Further Value

…

Earnings call: PTC Therapeutics updates on Q2 2024 financials & trials By Investing.com

Earnings call: PTC Therapeutics updates on Q2 2024 financials & trials…

PTC Therapeutics, Inc. (PTCT) Q2 2024 Earnings Call Transcript

…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

NEW YORK, Aug. 03, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

NEW YORK, July 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

Friedreichs Ataxia Market to Grow at a Substantial Growth Rate by 2034, Examines DelveInsight | Key Companies - Retrotope, PTC Therapeutics, Minoryx Therapeutics, Biogen, Lexeo Therapeutics, Larimar Therapeutics

The dynamics of Friedreichs ataxia market are anticipated to change as companies across the globe are thoroughly working toward the…

dpa-AFX ProFeed